131 related articles for article (PubMed ID: 38476010)
1. Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
Duch P; Díaz-Valdivia N; Gabasa M; Ikemori R; Arshakyan M; Fernández-Nogueira P; Llorente A; Teixido C; Ramírez J; Pereda J; Chuliá-Peris L; Galbis JM; Hilberg F; Reguart N; Radisky DC; Alcaraz J
Cancer Sci; 2024 May; 115(5):1505-1519. PubMed ID: 38476010
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic
Ikemori R; Gabasa M; Duch P; Vizoso M; Bragado P; Arshakyan M; Luis IC; Marín A; Morán S; Castro M; Fuster G; Gea-Sorli S; Jauset T; Soucek L; Montuenga LM; Esteller M; Monsó E; Peinado VI; Gascon P; Fillat C; Hilberg F; Reguart N; Alcaraz J
Cancer Res; 2020 Jan; 80(2):276-290. PubMed ID: 31694906
[TBL] [Abstract][Full Text] [Related]
3. Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma.
Duch P; Díaz-Valdivia N; Ikemori R; Gabasa M; Radisky ES; Arshakyan M; Gea-Sorlí S; Mateu-Bosch A; Bragado P; Carrasco JL; Mori H; Ramírez J; Teixidó C; Reguart N; Fillat C; Radisky DC; Alcaraz J
Matrix Biol; 2022 Aug; 111():207-225. PubMed ID: 35787446
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
Gabasa M; Ikemori R; Hilberg F; Reguart N; Alcaraz J
Br J Cancer; 2017 Oct; 117(8):1128-1138. PubMed ID: 28898237
[TBL] [Abstract][Full Text] [Related]
5. Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung.
Lugo R; Gabasa M; Andriani F; Puig M; Facchinetti F; Ramírez J; Gómez-Caro A; Pastorino U; Fuster G; Almendros I; Gascón P; Davalos A; Reguart N; Roz L; Alcaraz J
Oncotarget; 2016 Dec; 7(50):82324-82337. PubMed ID: 27384989
[TBL] [Abstract][Full Text] [Related]
6. 3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma.
Juste-Lanas Y; Díaz-Valdivia N; Llorente A; Ikemori R; Bernardo A; Arshakyan M; Borau C; Ramírez J; Ruffinelli JC; Nadal E; Reguart N; García-Aznar JM; Alcaraz J
Br J Cancer; 2023 Apr; 128(6):967-981. PubMed ID: 36572730
[TBL] [Abstract][Full Text] [Related]
7. Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.
Puig M; Lugo R; Gabasa M; Giménez A; Velásquez A; Galgoczy R; Ramírez J; Gómez-Caro A; Busnadiego Ó; Rodríguez-Pascual F; Gascón P; Reguart N; Alcaraz J
Mol Cancer Res; 2015 Jan; 13(1):161-73. PubMed ID: 25280968
[TBL] [Abstract][Full Text] [Related]
8. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
9. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.
Vizoso M; Puig M; Carmona FJ; Maqueda M; Velásquez A; Gómez A; Labernadie A; Lugo R; Gabasa M; Rigat-Brugarolas LG; Trepat X; Ramírez J; Moran S; Vidal E; Reguart N; Perera A; Esteller M; Alcaraz J
Carcinogenesis; 2015 Dec; 36(12):1453-63. PubMed ID: 26449251
[TBL] [Abstract][Full Text] [Related]
10. Smad3 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast Transition.
Tang PC; Chung JY; Xue VW; Xiao J; Meng XM; Huang XR; Zhou S; Chan AS; Tsang AC; Cheng AS; Lee TL; Leung KT; Lam EW; To KF; Tang PM; Lan HY
Adv Sci (Weinh); 2022 Jan; 9(1):e2101235. PubMed ID: 34791825
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
12. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
13. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.
Englinger B; Kallus S; Senkiv J; Heilos D; Gabler L; van Schoonhoven S; Terenzi A; Moser P; Pirker C; Timelthaler G; Jäger W; Kowol CR; Heffeter P; Grusch M; Berger W
J Exp Clin Cancer Res; 2017 Sep; 36(1):122. PubMed ID: 28882160
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
Kato R; Haratani K; Hayashi H; Sakai K; Sakai H; Kawakami H; Tanaka K; Takeda M; Yonesaka K; Nishio K; Nakagawa K
Br J Cancer; 2021 Mar; 124(5):914-924. PubMed ID: 33299131
[TBL] [Abstract][Full Text] [Related]
17. More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells.
Zhang SY; Hui LP; Li CY; Gao J; Cui ZS; Qiu XS
BMC Cancer; 2016 Feb; 16():171. PubMed ID: 26926340
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
19. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment.
Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q
Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.
Yamanaka T; Harimoto N; Yokobori T; Muranushi R; Hoshino K; Hagiwara K; Gantumur D; Handa T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Shirabe K
Br J Cancer; 2020 Mar; 122(7):986-994. PubMed ID: 32015511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
